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Solid tumour cells employ glycolytic enzymes including phosphoglycerate kinase (PGK) to make ATP when their supply of oxygen is
limiting. PGK is also secreted by tumour cells and facilitates cleavage of disulfide bonds in plasmin, which triggers proteolytic release of the
angiogenesis inhibitor, angiostatin. Although PGK production by tumour cells was enhanced by hypoxia, its secretion was inhibited.
Inhibition of secretion correlated with decrease in angiostatin formation by the tumour cells. In contrast, hypoxia did not inhibit the secretion
of the angiogenesis activator, vascular endothelial cell growth factor (VEGF). PGK secretion was reversed by normoxia and was under
control of the oxygen-sensing protein hydroxylases, as inhibitors of this class of enzymes mimicked the effect of hypoxia on PGK secretion.
Direct hydroxylation of PGK was not the mechanism by which the protein hydroxylases controlled its secretion. These findings show that
production and secretion of PGK are regulated separately and indicate that oxygen and the protein hydroxylases can control not only gene
expression but also protein secretion.
D 2003 Elsevier B.V. All rights reserved.Keywords: Phosphoglycerate kinase; Angiostatin; Hypoxia; Protein hydroxylase; Secretion1. Introduction
Tumour expansion and metastasis is dependent on angio-
genesis, which is controlled by several protein activators
and inhibitors [1]. One such inhibitor is angiostatin [2],
which is an internal fragment of the serine proteinase,
plasmin. Plasmin contains five consecutive triple-disulfide
linked domains, called kringle domains, followed by a serine
proteinase module. Angiostatin formation by tumour cells is
a three-step process. Plasminogen is first converted to
plasmin and then at least two disulfide bonds in the fifth
kringle domain are cleaved in a process that is facilitated by
tumour-derived phosphoglycerate kinase (PGK) [3]. The
modified plasmin is finally proteolysed by serine- and
metallo-proteinases to produce kringle 1–4 1
2
, 1–4 or 1–3
(reviewed in Ref. [4]).
PGK was named for its role in glycolysis, where it
catalyses phosphoryl transfer from 1,3-bisphosphoglycerate0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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to facilitate anaerobic production of ATP and angiogenesis
activators such as vascular endothelial cell growth factor
(VEGF) that trigger new blood vessel formation and enable
the tumour to grow (reviewed in Ref. [5]). Production of
angiostatin by tumour cells in response to hypoxia would be
counterproductive.
We show herein that although PGK production by
different tumour cells is enhanced by hypoxia, its secretion
is inhibited. The hypoxia-mediated inhibition of PGK se-
cretion was reversible by normoxia and was mimicked by
inhibitors of the oxygen-sensing protein hydroxylases. Di-
rect hydroxylation of PGK was not the mechanism by which
the protein hydroxylases controlled its secretion.2. Materials and methods
2.1. Hypoxic cell culture and collection of conditioned
medium and cell lysate
The medium of cells at f 80% confluence in T75 flasks
(f 7 106 cells) was replaced with 10ml of Hanks balanced
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cultured for 12 or 24 h under normoxic (20% O2) or hypoxic
( < 1% O2) conditions at 37 jC. On some occasions the hy-
poxia mimetics, desferrioxamine (DFO; Sigma, St. Louis,
MO) or dimethyloxalylglycine (DMOG; gift from Dr. Mur-
rayWhitelaw) was added to the HBSS. The hypoxic chamber
was a 2.5-l airtight container. A sachet of activated ascorbic
acid (Oxoid, Hampshire, England) was used to remove the
oxygen, which was confirmed with an anaerobic indicator
(Oxoid). The conditioned mediums were collected, centri-
fuged for 10 min at 3000 g to remove cell debris and stored
at  20 jC until analysis. Cell lysates were collected by
scraping the cells into 0.5 ml of ice cold 50 mM Tris, pH
8 buffer containing 0.5 M NaCl, 1% Triton X-100, 10 AM
leupeptin (Sigma), 100 AM 4-2-(aminoethyl)-benzene sulfo-
nyl fluoride (Sigma), 5 mM EDTA and 10 AM aprotinin
(Bayer, Sydney, Australia).
2.2. Production of anti-PGK antibodies
Balb/C mice were immunised with recombinant human
PGK produced in E. coli [3] and splenocytes from the
immunised mice were fused with the non-immunoglobu-
lin-secreting mouse myeloma cell line SP2/0. Hydridomas
were screened, cloned and isotyped and antibody was
produced in mouse ascites. Monoclonal anti-PGK IgM
antibodies were purified by SP-Sepharose ion-exchange
chromatography from ascites fluid. Polyclonal anti-PGK
antibodies were produced in sheep and affinity purified on
a column of the antigen linked to Sepharose CL-4B (Amer-
sham, Uppsala, Sweden).
2.3. ELISAs for PGK and VEGF
The anti-PGK murine IgM antibodies (100 Al of 5 Ag
ml 1 in 0.1 M NaHCO3, pH 8.3 buffer containing 0.02%
NaN3,) were adsorbed to Nunc MaxiSorp 96-well plates
overnight at 4 jC in a humid environment. Nonspecific
binding sites were blocked with 2% BSA and conditioned
medium (100 Al) or cell lysate (1:10 dilution with binding
buffer; 20 mM HEPES, pH 7.4 buffer containing 0.14 M
NaCl, 1 mM EDTA, and 0.05% Tween-20) was added to the
antibody-coated wells and incubated for 30 min at room
temperature with orbital shaking. The wells were then
washed three times with binding buffer and 100 Al of 20
Ag ml 1 of affinity purified anti-PGK sheep polyclonal
antibodies in binding buffer was added and incubated for 30
min at room temperature with orbital shaking. The wells
were then washed three times with binding buffer, before the
addition of 100 Al of a 1:5000 dilution of horseradish
peroxidase-conjugated rabbit anti-sheep IgG antibodies
(Dako, Glostrup, Denmark) in binding buffer. After incu-
bation for 30 min at room temperature with orbital shaking,
the wells were washed three times with binding buffer. The
colour was then developed with 100 Al of 0.003% H2O2, 1
mg ml 1 2,2V-azino-bis(3-ethyl-benzthiazoline-6-sulfonicacid) in 50 mM citrate, pH 4.5 buffer. There was a linear
relationship between absorbance at 405 nm and PGK
concentration up to 250 ng ml 1.
VEGF levels in conditioned mediums were measured
using a VEGF accucyte EIA kit from Oncogene Research
Products (CN Biosciences, San Diego, CA).
2.4. Angiostatin assay
Conditioned mediums (0.5 ml) were incubated with
plasmin (2 Ag ml 1) for 30 min at 37 jC and the angiostatin
fragments were labeled with a biotin-linked maleimide,
collected on lysine-Sepharose beads and detected using
peroxidase-conjugated avidin as described previously [6].
2.5. Detection of PGK mRNA
Following incubation in hypoxic or normoxic conditions,
HT1080 cells (7 106) were lysed in TRIZOL buffer
(Gibco) and total RNA extracted as described by the
manufacturer. The RNA (20 Ag) was blotted onto Nylon
Hybond transfer membrane (Amersham) and probed with
[32P] dCTP-labelled riboprobes complementary to PGK or
ribosomal protein S14 mRNA.
2.6. Peptide mass fingerprinting of secreted PGK
Ten litres of conditioned medium of HT1080 cells was
prepared using Nunc Cell Factories and the secreted PGK
was purified by Cibachron Blue-Sepharose and Heparin-
Sepharose affinity chromatography [3,6]. Fractions from the
Heparin-Sepharose affinity chromatography containing
PGK were concentrated, resolved on 4–20% gradient iGels
(Gradipore, Sydney, Australia) and stained with Coomassie
brilliant blue (Sigma). Gel slices containing PGK were
reduced, carbamidomethylated and digested with trypsin
(20 Ag ml 1; Roche Diagnostics, Basel, Switzerland) or
GluC (20 Ag ml 1; Roche Diagnostics) overnight at 37 jC.
Digested peptides were resolved on a C18 RP silica column
(PEPMAP, 75 Am 15 cm, LC-Packings) and analysed
using an API QStar Pulsar i hybrid tandem mass spectrom-
eter (Applied Biosystems, Foster City, CA). A TOF MS
survey scan was acquired (m/z 350–1700, 0.5 s) and the two
largest multiply charged ions (counts>10) sequentially se-
lected by Q1 for MS-MS analysis. A processing script
generated data suitable for submission to the database search
programs (Mascot, Matrix Science or SEQUEST).3. Results
3.1. Hypoxia stimulated PGK gene expression but inhibited
PGK secretion and angiostatin formation
Human fibrosarcoma HT1080 cells were exposed to
normoxia or hypoxia for 24 h and analysed for PGK gene
Fig. 2. Comparison of PGK secretion and angiostatin formation by tumour
and non-tumour cell lines and effect of hypoxia. Tumour (HT1080,
SU.86.86 and MDA-231) or non-tumour (BAEC and HFF) cells were
exposed to normoxia (closed bars) or hypoxia (open bars) for 24 h and the
conditioned mediums analysed for secreted PGK (A) and angiostatin
formation (B). The bars and errors represent the meanF S.E. of triplicate
measurements. The result is representative of two to six experiments.
Fig. 1. Hypoxia stimulated PGK gene expression but inhibited PGK
secretion and angiostatin formation. HT1080 cells were exposed to
normoxia or hypoxia for 24 h and analysed for PGK gene expression
(A), PGK cellular protein (B), secreted PGK (C), and angiostatin formation
(D) in the conditioned medium. RPS14 mRNA controlled for PGK mRNA
in (A). The bars and errors represent the meanF S.E. of triplicate
measurements. The result is representative of three experiments.
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angiostatin formation in the conditioned medium (Fig. 1). In
accordance with previous studies [7], hypoxia stimulated
PGK gene expression. PGK mRNA and cellular protein
increased 2.4- and 4.0-fold, respectively. In contrast, PGK
secretion was inhibited by hypoxia. The concentration of
PGK in the conditioned medium of cells exposed to hypoxia
was 10% of that for cells exposed to normoxia. Secreted
PGK levels correlated with the angiostatin-generating activ-
ity. The angiostatin-generating activity of the conditioned
medium of cells exposed to hypoxia was 12% of that for
cells exposed to normoxia.
The effect of hypoxia on PGK secretion was not a
secondary effect of change in pH of the culture medium
during the 24-h incubation. This was confirmed by buffering
the culture medium (HBSS) with 50 mM HEPES, pH 7.2.
PGK secretion was similarly inhibited following exposure to
hypoxia and there was no detectable change in the pH of the
culture medium.
3.2. Comparison of PGK secretion and angiostatin
formation by tumour and non-tumour cell lines and effect
of hypoxia
Tumour cells secrete much more angiostatin-generating
activity than other cells [8] and plasma of mice bearingHT1080 tumours contained several-fold more PGK than
mice without tumours [3]. These findings implied that
relatively small amounts of PGK were secreted from un-
transformed cells.
The effect of hypoxia on PGK secretion by different
tumour cell lines and non-tumour cells was measured.
Hypoxia inhibited secretion of PGK from human pancreatic
(SU.86.86) and mammary carcinoma (MDA-231) cell lines,
similarly to that observed for HT1080 cells (Fig. 2A). The
concentration of PGK in the conditioned medium of
SU.86.86 or MDA-231 cells exposed to hypoxia was 30%
and 40%, respectively, of that for cells exposed to normoxia.
Bovine endothelial (BAE) cells secreted small but detect-
able levels of PGK, which was slightly enhanced by
hypoxia, while human fibroblasts (HFF) did not secrete
detectable levels of PGK either under normoxic or hypoxic
conditions (Fig. 2A).
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ing activity of the different cell types (Fig. 2B). The
angiostatin-generating activity of the conditioned medium
of SU.86.86 or MDA-231 cells exposed to hypoxia was
34% and 52%, respectively, of that for cells exposed to
normoxia.
The results of Figs. 1 and 2 indicate that carcinoma cells
secrete significant amounts of PGK and that the level of
secretion is controlled by the oxygen concentration of the
culture medium.
3.3. Hypoxia inhibited PGK, but not VEGF, secretion from
tumour cells
Expression of the VEGF gene, like the PGK gene, is
controlled by oxygen. In contrast to secretion of PGK (Fig.
3A), hypoxia did not inhibit secretion of VEGF from
HT1080 cells (Fig. 3B). Secretion of VEGF was enhanced
by hypoxia, which is in accordance with enhanced expres-
sion of the protein. This result indicated that not all
oxygen-responsive proteins are also regulated at the level
of secretion.Fig. 3. Hypoxia inhibited PGK, but not VEGF, secretion from tumour cells.
HT1080 cells were exposed to normoxia or hypoxia for 24 h and the
conditioned mediums analysed for secreted PGK (A) and VEGF (B). The
result is representative of six experiments. (C) shows that the effect of
hypoxia on PGK secretion is reversible by normoxia. HT1080 cells were
exposed to normoxia or hypoxia for 12 h. The medium was replaced in both
flasks, which were then exposed to normoxia for a further 12 h ( + 20% O2).
The conditioned mediums were analysed for secreted PGK. The bars and
errors represent the meanF S.E. of triplicate measurements. The result is
representative of two experiments.
Fig. 4. Inhibitors of dioxygenases mimicked the effect of hypoxia on PGK
secretion. HT1080 cells were exposed to normoxia, hypoxia, or normoxia
in the presence of 100 AM DFO or 1 mM DMOG for 24 h and the cells
analysed for PGK protein and the conditioned mediums for secreted PGK.
The bars and errors represent the meanF S.E. of triplicate measurements.3.4. Inhibition of PGK secretion by hypoxia was reversible
Inhibition of secretion of PGK by hypoxia was re-
versed by exposure to normoxic conditions. HT1080 cells
were exposed to normoxia or hypoxia for 12 h, the
medium was replaced and then both flasks of cells were
exposed to normoxia for a further 12 h. The level of
secreted PGK in the second 12 h of normoxic exposure
was the same in both flasks (Fig. 3C). This result implied
that the hypoxic-dependent events that mediated inhibition
of PGK secretion were reversed within hours by nor-
moxic conditions.
3.5. Inhibitors of dioxygenases mimicked the effect of
hypoxia on PGK secretion
It seemed likely that the hypoxia-mediated inhibition of
PGK secretion was regulated by the same oxygen sensors
that mediate oxygen-dependent gene expression, the protein
hydroxylases. This theory was tested be examining the
effect of protein hydroxylase inhibitors on PGK secretion
by tumour cells.
The result is representative of three experiments.
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nated by histidine and aspartic acid residues. Oxygen binds
to the ferrous state of the iron and one oxygen atom is
transferred onto proline or asparagine residues while the
other reacts with 2-oxoglutarate yielding succinate and
carbon dioxide. Chelation of the iron with DFO inactivates
the hydroxylases. DMOG is a competitive substrate ana-
logue that also inactivates the hydroxylases.
DFO and DMOG mimicked the effect of hypoxia on
PGK gene expression and protein secretion (Fig. 4). For
example, treatment with 1 mM DMOG increased cellular
PGK levels 6.5-fold, while secretion of PGK was 4% of
control. The result directly implicates the protein hydrox-
ylases in oxygen-dependent control of PGK secretion.
3.6. Secreted PGK was not hydroxylated
It was possible that direct hydroxylation of PGK by the
protein hydroxylases was targeting it for secretion. This
notion was tested by examining the secreted protein for
hydroxylated Asn or Pro residues. In-gel reduction and
carbamidomethylation of Cys residues followed by diges-
tion with trypsin or GluC and MS/MS spectrometry identi-
fied peptides covering the entire sequence of PGK,
suggesting that no posttranslational modifications had oc-
curred prior to secretion. In addition, allowing hydroxyla-
tions (mass addition + 16 on Asn and Pro) while searching
the obtained MS/MS data identified no modified peptides
(data not shown). Taken together, these data show that the
secreted PGK was not hydroxylated.4. Discussion
The correct and efficient localization of nascent cyto-
solic polypeptides is mediated by specific sorting or
targeting sequences. Most proteins destined for secretion
contain a recognisable N-terminal signal sequence that
mediates their translocation across the endoplasmic retic-
ulum (ER) membrane, which commits them to the exo-
cytotic pathway [9]. PGK is a new member of a growing
family of proteins that are secreted despite not having an
identifiable signal sequence [10].
Several proteins that lack a signal sequence have been
found to have a defined extracellular function [11]. These
include thioredoxin, annexin 1, platelet-derived growth fac-
tor, fibroblast growth factors 1 and 2, interleukin-1, trans-
glutaminase, and coagulation factor XIIIa, among others
[12]. These proteins and PGK [13] share some biochemical
features such as lack of N-linked glycosylation at potential N-
X-S/T sites and presence of cysteines but lack of disulfide
bonds. The fact that glycosylation and disulfide bond forma-
tion take place in the ER suggests that these proteins exit the
cell by a means other than the classical ER–Golgi route.
Increase in expression usually translates to increased
secretion for proteins that exit via the ER–Golgi route [9].Secretion of signal-less proteins on the other hand is often
associated with cellular stress and may not reflect expres-
sion levels of the protein [12,14]. PGK is the first example
of oxygen-dependent control of protein secretion, including
proteins that either contain or lack a secretory signal
sequence.
Many factors come into play to ensure that the right
amount of oxygen reaches cells throughout the body.
Specific prolyl and asparaginyl hydroxylases [15,16] and
the transcription factor HIF-1 [17–20] underpin many of the
biological responses to oxygen deprivation in mammalian
cells, including angiogenesis, red cell production and cellu-
lar metabolism (including PGK expression) (reviewed in
Ref. [5]). As oxygen is a co-substrate for the hydroxylases,
its concentration controls their activity. HIF-1 is a hetero-
dimer composed of a and h subunits. Hydroxylation of two
proline residues (Pro402 and Pro564) in the oxygen-depen-
dent degradation domain of HIF-1a confers rapid degrada-
tion, while hydroxylation of two asparagine residues
(Asn803 and Asn851) in the C-terminal trans-activation
region regulates HIF-1a activity.
PGK secretion was under the control of the protein
hydroxylases, as inhibitors of these enzymes mimicked the
effects of hypoxia on PGK secretion. Direct hydroxylation
of PGK, however, was not the mechanism by which the
protein hydroxylases controlled its secretion.
It is possible that a component of the secretory
pathway used by PGK was activated by hydroxylation,
which enabled PGK secretion under normoxic conditions.
Under hypoxic conditions the secretory component was
not hydroxylated and therefore PGK secretion was turned
off. This model is analogous to the control of HIF-1
degradation and activity by protein hydroxylation. An-
other possibility is that the product of one or more HIF-
1a regulated genes may negatively regulate PGK secre-
tion. HIF-1a controls the expression of at least 30 genes
when oxygen levels are low [21]. None of the genes
identified so far have been implicated in protein export,
however.
Oxygen-dependent control of PGK secretion may be a
useful handle to probe the nature of the illusory nonclassical
secretory pathway. More generally, these observations indi-
cate that oxygen and the protein hydroxylases can control
not only gene expression but also protein secretion. Eluci-
dation of the mechanism by which the hydroxylases can
control protein secretion may provide an important insight
into tumour biology.Acknowledgements
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